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ABSTRACT 
The work seeks to present nanotechnology forms of drug delivery and how it would improve treatment effects to patients. 
Nanotechnology forms of drug delivery not only offer many options for cancer patients using chemotherapeutic drugs, but it also has 
much more alternative uses and this review will seek to present data on the same.  
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In the treatment of cancer, different forms of 
chemotherapeutic drugs are used. The drugs have a 
significant advantage for patient therapy but they have 
some disadvantages as well. They are toxic. They have poor 
tissue selectivity. They have a narrow therapeutic window 
and the continued use of such drugs would lead to drug 
resistance1-9. Toxicity is related to the action of drugs on all 
cells (the cancer cells as well as healthy tissue cells) which 
would result in the death of the healthy tissue cells. A 
selectively targeted drug delivery system is needed to 
improve the prognosis for the patient. This is done with the 
help of nanotechnology. With nanotechnology, it is possible 
to prepare nanoparticles with different size, shapes, 
chemical, and physical properties10-16. Due to their unique 
size, the range of nanoparticles exhibit and more, an 
“enhanced permeability and retention effect” (EPR) is 
observed. This helps the drugs to specifically target and 
accumulate in the tumor cells. The work reviews the 
nanotechnology implementation of drug delivery and its 
efficacy with the help of existing secondary research 
studies.  
Nanotechnology forms of delivery 
Two ways to load the drug in the delivery vehicle in 
nanotechnology forms of delivery are by means of non-
covalent encapsulation and covalent conjugation. In non-
covalent encapsulation, the drug molecules interact with 
the delivery materials by non-covalent bonding, which 
offers advantages of adjusting the ratio of dose and 
multidrug combination. However, the weak non-covalent 
nature would normally lead to instability in drug 
releases17-23. 
In covalent conjugation, both the drugs and the delivery 
materials are chemically bonded together, enabling the 
delivery vehicle as a predictable profile. This is a necessity 
in all treatment plans. The Captothecin CPT, which is 
derived from Chinese tree Camptotheca, exhibits very 
strong cytotoxicity and hence it offers much value for 
cancer treatment. As tested in vivo and in vitro, it is 
identified that CPT is a DNA topoisomerase inhibitor. The 
efficacy of CPT is primarily due to the formation of the 
tertiary complex between topoisomerase, DNA and CPT. 
Rapid accumulation of Cancer DNA is thus terminated. 
Some issues are noticed in the treatment delivery. 
However, for instance, the instability of the e-lactone ring 
in CPT leads to the formation of carboxylate forms that are 
inactive. CPT derivates approved by the FDA are helpful for 
the treatment of cancers of the ovary and colon cancer as 
well. There are pros of using CPT as CPT has a 5-membered 
ring system and this system makes the compound better in 
hydrophobic delivery24-32. 
The advantages of the CPT make it a model compound to be 
used in drug delivery. Especially in the case of hydrophobic 
drug delivery, it is identified that nanoparticles in their 
simple assembly need a hydrophilic structure and, in this 
CPT, it can be used. Natural amino acids and peptides 
structures are used for drug delivery. They do have 
biocompatibility and also reduced systemic toxicity. 
Ethylene glycol is used as a hydrophilic part as well. In self-
assembly of polymers, disulfide bonding is used for the 
purpose of cross-linking. Stability is always an issue in drug 
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delivery and in the use of nanotechnology with some of 
these natural peptide structures, it has been identified that 
stability is corrected to a certain extent. A CPT conjugated 
cross-linked micelles structure with built-in the disulfide 
bond, for instance, can be broken down faster into the 
bloodstream. It diffuses faster into the bloodstream.  
With drug resistance and other serious issues happening in 
traditional treatment methods, the use of nanotechnology 
can aid in better imparting of multiple drug treatment to 
patients. The use of nanotechnology helps address the 
issues of cytotoxicity happening in cancer drug treatments. 
In the case of aggressive cancer, it is necessary to load 
much medicine as a single delivery option in order to slow 
down the rapid abnormal proliferation33-36. However, this 
form of medicine loading, in turn, does damage to the 
person’s health as their normal cells and tissues are 
targeted as well. The efficacy of the chemotherapeutic 
drugs hence has to be re-analyzed. In this context, 
nanotechnology delivery forms become important.  
Additionally, as Yang et al. and Sun et al. highlight, 
nanotechnology does need to be useful in certain medical 
contexts. Yang et al., for instance, argue the efficacy of the 
medicine when it comes to early detection of tumors. Early 
detection of tumors would spell better prognosis for the 
patient. Here nanotechnology is not only playing the role of 
a treatment plan, but it is also playing the role of a 
proactive agent when it comes to treating cancer. Similarly, 
as Sun et al. highlight, the blood-brain BBB barrier that can 
be crossed by nanotechnology helps deliver psychosis 
drugs in a better way to patients without affecting their 
other normal cells. Targeted deliveries and improved and 
overall treatment plans improve as well.  
Conclusion 
Multiple drugs are used with one vehicle such as a nano-
drug delivery method. Nanotechnology holds many 
advantages for chemotherapeutic interventions and 
although scientists have produced various treatments of 
drugs with targeted delivery options, none are as receptive 
as the combined nanotechnology and peptide options. It is 
recommended that more research can be carried out on 




1. Qiao, H., et al. Redox-triggered mitoxantrone prodrug micelles 
for overcoming multidrug-resistant breast cancer. Journal of 
drug targeting 2018; 26:75-85. 
2. Kang, C., Qin, J., Osei, W. & Hu, K. Regulation of protein kinase 
C-epsilon and its age-dependence. Biochemical and Biophysical 
Research Communications 2017; 482:1201-1206). 
3. Sun, Y., et al. RGD Peptide‐Based Target Drug Delivery of 
Doxorubicin Nanomedicine. Drug development research 2017; 
78:283-291. 
4. Kang, C. & Hu, K. Role of caveolin-3 in adenosine-induced 
increase in mitochondrial PKCε. The FASEB Journal 2013; 
27:1191.1197-1191.1197. 
5. Cheng, X. & Lee, R.J. The role of helper lipids in lipid 
nanoparticles (LNPs) designed for oligonucleotide delivery. 
Adv Drug Deliv Rev 2016; 99:129-137. 
6. Sun, Y. & Kang, C. Self-Assembly of Peptides into Hydrogel. 
Journal of Organic & Inorganic Chemistry 2016; 2:5. 
7. Yao, Z., Sun, Y. & Kang, C. Structure and self-assembly of 
multicolored Naphthalene Diimides Semiconductor. Nano LIFE 
2016; 6:1642007. 
8. Cheng, X., et al. T7 Peptide-Conjugated Lipid Nanoparticles for 
Dual Modulation of Bcl-2 and Akt-1 in Lung and Cervical 
Carcinomas. Molecular pharmaceutics 2018; 15:4722-4732. 
9. Zhong, X., Sun, Y., Kang, C. & Wan, G. The theory of 
dielectrophoresis and its applications on medical and 
materials research. European Journal of BioMedical Research 
2017; 2:7-11. 
10. Fan, S. & Chi, W. Methods for genome-wide DNA methylation 
analysis in human cancer. Brief Funct Genomics 2016; 15:432-
442. 
11. Kang, C. & Hu, K. Modulation of the two-pore domain 
potassium channel TASK-1 by caveolin-3. The FASEB Journal 
2015; 29:845.814. 
12. Kang, C., Sun, Y., Wang, M. & Cheng, X. Nanosized camptothecin 
conjugates for single and combined drug delivery. European 
Journal of BioMedical Research 2016; 2:8-14. 
13. Qiao, H., et al. Orally delivered polycurcumin responsive to 
bacterial reduction for targeted therapy of inflammatory 
bowel disease. Drug Delivery 2017; 24:233-242. 
14. Liu, F., Sun, Y., Kang, C. & Zhu, H. Pegylated Drug Delivery 
Systems: From Design to Biomedical Applications. Nano LIFE 
2016; 6:1642002. 
15. Sun, Y., Kang, C., Yao, Z., Liu, F. & Zhou, Y. Peptide-Based Ligand 
for Active Delivery of Liposomal Doxorubicin. Nano Life 2016; 
6:1642004. 
16. Fan, S., Huang, K., Ai, R., Wang, M. & Wang, W. Predicting CpG 
methylation levels by integrating Infinium 
HumanMethylation450 BeadChip array data. Genomics 2016; 
107:132-137. 
17. Waller, A.P., et al. GLUT12 functions as a basal and insulin-
independent glucose transporter in the heart. Biochimica et 
Biophysica Acta (BBA)-Molecular Basis of Disease 2013; 
1832:121-127. 
18. Li, Q., et al. Identification by shape-based virtual screening and 
evaluation of new tyrosinase inhibitors. PeerJ 2018; 6:e4206. 
19. Chen, Y., et al. Identification of 4-aminoquinoline core for the 
design of new cholinesterase inhibitors. PeerJ 4, e2140 (2016). 
20. Kang, C. & Hu, K. Impact of hypoxia in the expression and 
regulation of the TASK-1 potassium channel in cardiac 
myocytes. The FASEB Journal 2016; 30;lb598-lb598. 
21. Kang, C. Ion channels, protein kinase C and caveolae in 
cardioprotection, (The Ohio State University, 2015). 
22. Yung, B.C., et al. Lipid nanoparticles composed of quaternary 
amine–tertiary amine cationic lipid combination (QTsome) for 
therapeutic delivery of AntimiR-21 for lung cancer. Molecular 
pharmaceutics 2016; 13:653-662. 
23. Cheng, X., et al. Lipid Nanoparticles Loaded with an Antisense 
Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung 
Cancer. Pharmaceutical research 2017; 34:310-320. 
24. Song, L., et al. Crocetin inhibits lipopolysaccharide-induced 
inflammatory response in human umbilical vein endothelial 
cells. Cellular Physiology and Biochemistry 2016; 40:443-452. 
25. Sun, Y., Kang, C., Liu, F. & Song, L. Delivery of antipsychotics 
with nanoparticles. Drug Development Research 2016; 77:393-
399. 
26. Kang, C., et al. Delivery of nanoparticles for treatment of brain 
tumor. Current Drug Metabolism 2016; 17:745-754. 
27. Xue, X., et al. Discovery of novel inhibitors disrupting HIF-
1α/von Hippel–Lindau interaction through shape-based 
screening and cascade docking. PeerJ 2016; 4:e2757. 
Zhang et al                                                                                                                              Journal of Drug Delivery & Therapeutics. 2018; 8(6):275-277  
ISSN: 2250-1177                                                                                   [277]                                                                                   CODEN (USA): JDDTAO 
28. Hersch, S.J., et al. Divergent protein motifs direct elongation 
factor P-mediated translational regulation in Salmonella 
enterica and Escherichia coli. MBio 2013; 4:e00180-00113. 
29. Shuhong, X., et al. Dynamic expression of AQP4 in early stageof 
ischemia/reperfusion rats and cerebral edema. Chinese 
Pharmacological Bulletin 2016; 32:1433-1441. 
30. Peng, J., et al. Enhanced Liver Regeneration After Partial 
Hepatectomy in Sterol Regulatory Element-Binding Protein 
(SREBP)-1c-Null Mice is Associated with Increased 
Hepatocellular Cholesterol Availability. Cellular Physiology and 
Biochemistry 2018; 47:784-799. 
31. Yang, Z., et al. Functional exosome-mimic for delivery of siRNA 
to cancer: in vitro and in vivo evaluation. Journal of Controlled 
Release 2016; 243:160-171. 
32. Kang, C., Hernandez, V.A. & Hu, K. Functional interaction of the 
two-pore domain potassium channel TASK-1 and caveolin-3. 
Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 
2017; 1864:1537-1544. 
33. Kang, C., Qin, J., Osei, W. & Hu, K. Age-dependent Mitochondrial 
Targeting Of Protein Kinase C Epsilon In Cardioprotection. The 
FASEB Journal (2017). 
34. Han, R., Sun, Y., Kang, C., Sun, H. & Wei, W. Amphiphilic 
dendritic nanomicelle-mediated co-delivery of 5-fluorouracil 
and doxorubicin for enhanced therapeutic efficacy. Journal of 
Drug Targeting 2017; 25:140-148. 
35. Sun, Y., et al. Co-delivery of dual-drugs with nanoparticle to 
overcome multidrug resistance. European Journal of 
BioMedical Research 2016; 2:12-18. 
36. Liu, F., Sun, Y. & Kang, C. Controlling Amphiphilic Functional 
Block Copolymers’ Self-Assembly: From Structure to Size. 
(2016).
 
 
